American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Enlivex Ltd. (ENLV)

$4.20 -3.67% NASDAQ: ENLV · 15-min delayed

Public · NASDAQ: ENLV
34 employees

Visit website Follow

$171.1MMarket cap

$1.2BNet income

34Employees

ENLVNASDAQ

2014IPO

About Enlivex Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: ENLV
Employees: 34
IPO date: Jul 31, 2014
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ENLV Nasdaq
SEC CIK: 1596812
SIC: 2834 Pharmaceutical Preparations

Embed this company’s badge

Show Enlivex Ltd.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/enlivex-ltd/"><img src="https://americancompanies.com/badge/enlivex-ltd.svg" alt="Enlivex Ltd. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Enlivex Ltd. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: $1.2B
Total assets: $2.3B
Market cap: $171.1M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ENLV

$4.20 -3.67%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.20 $27.30

52-week range

Market cap: $171.1M
Shares outstanding: 40.7M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 31, 2014

Enlivex Ltd. (ENLV) Stock Price

Profitable — net income of $1.2B.
Trading 85% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Enlivex Ltd..

Write a review

Newsroom

News about Enlivex Ltd.

RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch GlobeNewswire Inc. · 2026-06-05 · positive Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis GlobeNewswire Inc. · 2025-08-18 · positive Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis GlobeNewswire Inc. · 2024-10-30 · positive Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis GlobeNewswire Inc. · 2024-06-17 Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering GlobeNewswire Inc. · 2024-05-29 Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering GlobeNewswire Inc. · 2024-05-28

News & sentiment via Polygon.io

FAQ

Enlivex Ltd.: frequently asked questions

Is Enlivex Ltd. an American company?

Enlivex Ltd. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Enlivex Ltd. publicly traded?

Yes — Enlivex Ltd. is a publicly traded company. Its stock trades under the ticker symbol ENLV on the NASDAQ.

What does Enlivex Ltd. do?

Enlivex Ltd. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore